The FDA has awarded Fast Track designation to two drugs currently in development for CMT.
Daniel Levine from Global Genes speaks with Allison Moore on the Global Genes Rare Cast.
HNF to host an educational CMT symposium at AANEM’s Annual Conference October 10-13th in Washington, D.C.
True Reply and HNF have collaborated to enhance patient focused research and knowledge of what matters most to patients living with CMT.
StarWise Therapeutics LLC & HNF join forces to expedite the advancement of a new drug entity to the clinic for the treatment of CMT2A.
Enrollment and treatment are ongoing in Part 1 of the Phase 2 trial of ACE-083 in patients with CMT disease.
Learn how this CMT1A patient uses the AlterG treadmill to manage her CMT symptoms.